This set covers the foundational pharmacology of vasopressin — the hormone your body uses to hold onto water — and the drugs that mimic it, block it, or exploit its signaling for clinical purposes. You will encounter three drug categories that act on the same receptor system in opposing directions: vasopressin itself (an agonist used in shock), desmopressin (a selective analog used in diabetes insipidus and bleeding disorders), and the vaptans (antagonists used to correct dangerous low-sodium states). You will also work through the pathology that makes these drugs necessary — SIADH, a condition in which the hormone keeps firing when it should be silent, and the life-threatening complication that can follow if the sodium is corrected too quickly.
Some of the early questions are straightforward vocabulary — the kind a well-prepared student should get right without much deliberation. The later questions will ask you to connect concepts you have already seen: why a drug that corrects sodium can also cause fatal hypernatremia in the wrong patient, or why a drug used to stop bleeding is contraindicated in one subtype of the very disease it treats. These are not trick questions — they follow directly from the mechanisms. Read every rationale, including the ones for questions you answer correctly. The rationales are where the teaching happens.
1. AVP (arginine vasopressin — also called antidiuretic hormone or ADH) is a small peptide hormone released from the posterior pituitary gland. It acts on two different receptor types in two different organs to produce two distinct physiological effects. Which of the following correctly identifies both major actions of AVP?
A) AVP stimulates the heart to increase cardiac output and simultaneously stimulates the kidneys to excrete sodium, raising blood pressure through volume expansion rather than vasoconstriction.
B) AVP promotes water excretion by the kidneys to lower plasma osmolality, and simultaneously dilates blood vessels to reduce blood pressure during states of volume excess.
C) AVP acts on the kidneys to reduce water excretion and concentrate urine (antidiuresis), and acts on blood vessel walls to cause constriction and raise blood pressure (vasoconstriction) — making it both an antidiuretic hormone and a vasopressor.
D) AVP acts exclusively on the kidneys to regulate water balance; its name "antidiuretic hormone" reflects this single organ specificity, and vascular effects require separate catecholamine release.
E) AVP promotes sodium reabsorption in the kidney to correct hyponatremia, and stimulates aldosterone release from the adrenal gland to amplify that sodium retention.
ANSWER: C
Rationale:
AVP acts through two distinct receptor subtypes to produce two clinically important effects. At V2 receptors on collecting duct cells in the kidney, AVP reduces water excretion by triggering the insertion of water channels (aquaporin-2) into the tubular membrane — water is then reabsorbed from the urine back into the body, producing concentrated urine and lowering plasma osmolality. At V1a receptors on vascular smooth muscle cells, AVP causes vasoconstriction that raises blood pressure. These two properties are exploited in clinical practice: the antidiuretic effect is the target in diabetes insipidus and SIADH management, and the vasopressor effect is exploited when vasopressin is infused in septic shock. Understanding that a single hormone serves both functions explains why the synthetic analog desmopressin was engineered to preserve only the kidney effect while eliminating the vascular effect — making it safer for repeated outpatient use.
Option A: Option A is incorrect: AVP does not stimulate cardiac output or promote sodium excretion; its renal action is to retain water (antidiuresis), not to excrete sodium, and its vascular action is vasoconstriction, not vasodilation.
Option B: Option B is incorrect: AVP reduces water excretion (retains water, concentrates urine) rather than promoting water excretion; its vascular effect is vasoconstriction, not vasodilation — these are the opposite of what option B states.
Option D: Option D is incorrect: AVP has well-established vascular effects through V1a receptors on smooth muscle; its role as a vasopressor in septic shock and its use in vasodilatory hypotension directly reflect this non-renal action.
Option E: Option E is incorrect: AVP does not promote sodium reabsorption directly; its renal action is on water handling through AQP2 water channels, not sodium transport; aldosterone (regulated primarily by angiotensin II and potassium) is the hormone responsible for sodium reabsorption.
2. When AVP is present in the bloodstream, it binds to receptors (called V2 receptors) on cells lining the collecting duct of the kidney. This triggers a chain of events that makes the urine more concentrated. Which of the following correctly identifies what happens inside the collecting duct cell when AVP activates its receptor?
A) AVP causes water channel proteins called AQP2 (aquaporin-2) to move from storage inside the cell to the membrane facing the urine — once inserted, these channels allow water to flow from the urine back into the body, concentrating the urine; without AVP these channels stay stored inside the cell and urine remains dilute.
B) AVP causes the collecting duct cell to actively pump sodium out of the urine and into the body; water follows the sodium by osmosis, concentrating the urine as a secondary effect of sodium transport rather than through dedicated water channels.
C) AVP opens calcium channels on the surface of collecting duct cells, allowing calcium to enter; the calcium triggers contraction of the cell, physically squeezing water out of the tubular lumen and back into the bloodstream.
D) AVP stimulates collecting duct cells to produce aldosterone locally; this locally produced aldosterone then opens sodium channels on the same cell, and water follows the sodium reabsorption as in the distal nephron.
E) AVP causes collecting duct cells to shrink, widening the gaps between cells; water then moves passively between cells (paracellularly) from the dilute urine into the more concentrated tissue fluid surrounding the tubule.
ANSWER: A
Rationale:
The molecular mechanism of AVP-driven urine concentration centers on the regulated trafficking of AQP2 (aquaporin-2) water channel proteins. Under basal conditions without AVP, AQP2 channels are stored in vesicles inside collecting duct principal cells — the luminal membrane has very few water channels and water cannot easily cross it, so dilute urine passes through. When AVP binds V2 receptors, it activates a signaling chain (Gs protein → adenylyl cyclase → cyclic AMP → protein kinase A) that phosphorylates AQP2 vesicles and causes them to fuse with the luminal membrane, inserting functioning water channels. The medullary tissue surrounding the tubule is highly concentrated (salty), so once water channels are open, water moves osmotically from the dilute urine through the AQP2 channels into the cell and then out the other side of the cell into the bloodstream — concentrating the urine. This mechanism is the pharmacological target of vaptans: by blocking V2 receptors, vaptans prevent AQP2 insertion and allow dilute urine to pass through, removing excess free water from the body and raising serum sodium.
Option B: Option B is incorrect: AVP-driven urine concentration is a water-selective process through dedicated water channels; sodium is not actively pumped by AVP at this site, and sodium transport is not the primary mechanism of urine concentration in the collecting duct.
Option C: Option C is incorrect: AVP acts through a cyclic AMP pathway in collecting duct cells, not through calcium channel opening or cell contraction; the mechanism is vesicle trafficking of water channels, not physical squeezing of fluid.
Option D: Option D is incorrect: aldosterone is produced in the adrenal gland, not locally in collecting duct cells; AVP and aldosterone are separate hormones with different receptors and different mechanisms; they can act together but AVP does not trigger local aldosterone production.
Option E: Option E is incorrect: AVP does not cause cell shrinkage or widen paracellular gaps; the water movement it drives is transcellular (through the AQP2 channels within the cells), not paracellular between cells.
3. AVP acts through two receptor subtypes called V1a and V2. Each is found in a different location and produces a different effect. Which of the following correctly matches each receptor to its location and primary effect?
A) V1a receptor: kidney collecting duct cells → water reabsorption; V2 receptor: blood vessel walls → vasoconstriction.
V1a and V2 receptors are the two principal AVP receptor subtypes with distinct tissue locations and physiological roles. V1a receptors are expressed on vascular smooth muscle cells in blood vessel walls; when AVP binds V1a receptors, it activates a signaling pathway (Gq protein) that causes intracellular calcium release and smooth muscle contraction — producing vasoconstriction. This is the basis for AVP's vasopressor effect in septic shock. V2 receptors are expressed on collecting duct principal cells in the kidney; when AVP binds V2 receptors, it activates a different signaling pathway (Gs protein → cyclic AMP) that causes AQP2 water channels to move to the luminal membrane — producing water reabsorption and concentrated urine. This is the basis for AVP's antidiuretic effect. The distinction between V1a (vascular, vasoconstriction) and V2 (kidney, antidiuresis) is clinically important because the drugs that block these receptors — vaptans — differ in their selectivity: tolvaptan blocks only V2 (no hemodynamic effect), while conivaptan blocks both V1a and V2 (causing both aquaresis and some blood pressure lowering).
Option A: Option A is incorrect: the receptor assignments are reversed; V1a is on blood vessel walls producing vasoconstriction, and V2 is on kidney collecting duct cells producing water reabsorption.
Option B: Option B is incorrect: V1a receptors are not on kidney collecting duct cells; sodium reabsorption is not the primary V1a-mediated renal action; aldosterone release is regulated by angiotensin II (AT1 receptors), not by AVP V2 receptors on the adrenal gland.
Option C: Option C is incorrect: while AVP (produced by parvocellular neurons) does play a minor role in pituitary ACTH regulation, V1a on the anterior pituitary producing ACTH release is not the primary physiological role of the V1a receptor and is not the standard teaching point; the established primary pairing is V1a on vascular smooth muscle.
Option E: Option E is incorrect: AVP does act on V1a receptors in the liver to stimulate glycogenolysis as a minor effect, but V2-mediated sodium excretion is not correct — V2 signaling in the kidney drives water reabsorption, not sodium excretion.
4. A pharmacology instructor describes a class of drugs called "vaptans" to a first-year medical student. Which of the following most accurately describes what vaptans are and what they do?
A) Vaptans are synthetic forms of AVP that bind V2 receptors more potently than the natural hormone, producing stronger antidiuresis and higher urine concentration — used to treat diabetes insipidus when natural AVP secretion is insufficient.
B) Vaptans are drugs that block AVP receptors in the kidney, preventing AVP from inserting water channels into collecting duct cells; instead of retaining water, the kidney excretes electrolyte-free water (a process called aquaresis), which raises the concentration of sodium in the blood — making vaptans useful for correcting low-sodium states (hyponatremia).
C) Vaptans are diuretics that work by blocking sodium transporters in the loop of Henle — the same mechanism as furosemide — but are classified separately because they selectively target the medullary thick ascending limb rather than the cortical segment.
D) Vaptans are aldosterone antagonists that block mineralocorticoid receptors in the collecting duct, preventing sodium reabsorption and causing mild water loss as a secondary effect — used to treat hypertension and heart failure edema.
E) Vaptans are drugs that block V1a receptors on blood vessel walls, producing vasodilation and lowering blood pressure; they are used in hypertensive emergencies as an alternative to calcium channel blockers.
ANSWER: B
Rationale:
The word "vaptan" is derived from "vasopressin antagonist" — this naming convention reflects the class mechanism. Vaptans competitively block AVP receptors (specifically V2 receptors in the most common agents, or both V1a and V2 in conivaptan), preventing AVP from triggering its downstream water-channel-insertion cascade. Because the collecting duct cells cannot insert AQP2 channels without AVP signaling, the dilute tubular urine passes through without being reabsorbed — the kidney excretes free water without losing the electrolytes sodium and potassium. This electrolyte-free water excretion is called aquaresis (to distinguish it from conventional diuresis, which removes both salt and water). The result is a rise in serum sodium concentration, which is the therapeutic goal in hyponatremia from SIADH or heart failure. The approved vaptans are tolvaptan (oral, V2-selective), conivaptan (intravenous, V1a and V2), and satavaptan (not FDA-approved).
Option A: Option A is incorrect: vaptans are receptor antagonists (blockers), not agonists or synthetic hormone replacements; desmopressin is the synthetic AVP analog used in diabetes insipidus — it is the opposite pharmacological category from a vaptan.
Option C: Option C is incorrect: vaptans have no activity at sodium transporters in the loop of Henle; that mechanism describes loop diuretics such as furosemide; vaptans act at AVP receptors in the collecting duct, not at sodium cotransporters in the loop.
Option D: Option D is incorrect: vaptans are AVP receptor antagonists, not aldosterone antagonists; spironolactone and eplerenone are mineralocorticoid receptor antagonists; the two drug classes act at completely different receptors through different mechanisms.
Option E: Option E is incorrect: while conivaptan does block V1a receptors and can cause some vasodilation and blood pressure lowering as a side effect, this is not the primary therapeutic mechanism or indication for vaptans; vaptans are used for hyponatremia, not as antihypertensive agents.
5. A hospitalized patient is found to have a low serum sodium of 122 mEq/L (normal 136–145 mEq/L). Further testing shows that the body's water-retaining hormone AVP is active even though plasma osmolality (the concentration of the blood) is already low — a situation where AVP should normally be suppressed. The patient appears neither dehydrated nor swollen. This pattern is called SIADH. What does the "I" in SIADH stand for, and what does it mean in plain language?
A) "Insufficient" — the body is not producing enough AVP to maintain normal sodium balance, and the hyponatremia results from a relative AVP deficiency causing excessive water loss.
B) "Intermittent" — AVP release occurs in unpredictable bursts rather than in the normal continuous low-level pattern, causing oscillating sodium levels that average to a low value over time.
C) "Inhibited" — normal osmoreceptor feedback has been inhibited by a drug or disease, so AVP is prevented from rising when it should — causing dilute urine and high sodium rather than low sodium.
D) "Induced" — an external drug or toxin has induced AVP secretion above the normal basal rate, but only in patients with pre-existing renal disease that prevents compensation.
E) "Inappropriate" — AVP is being released even though plasma osmolality is already low (a situation where normal physiology would suppress AVP completely); because AVP keeps the kidney retaining water when it should be excreting it, free water accumulates in the body and dilutes the sodium to abnormally low levels.
ANSWER: E
Rationale:
SIADH stands for Syndrome of Inappropriate Antidiuretic Hormone secretion. The word "inappropriate" captures the core pathophysiology precisely: under normal physiology, AVP secretion is suppressed when plasma osmolality falls below approximately 280 mOsm/kg, allowing the kidney to excrete dilute urine and correct any water excess. In SIADH, AVP continues to be secreted despite low plasma osmolality — either from the pituitary itself (due to brain disorders, pulmonary disease, or drugs), from ectopic sources such as tumors, or from drug-induced AVP-like effects. Because the AVP signaling is still active, the kidney keeps its collecting duct water channels (AQP2) open, reabsorbing free water continuously. The retained water dilutes the blood, lowering sodium — yet AVP does not switch off as it normally would, because the release is driven by a disease process rather than by physiological osmolality. The result is euvolemic (normal volume, neither dehydrated nor swollen) hypotonic (low blood concentration) hyponatremia (low sodium). Vaptans treat SIADH by blocking the AVP receptor in the kidney, overriding the inappropriate signal and allowing the excess free water to be excreted.
Option A: Option A is incorrect: SIADH involves excess AVP activity, not insufficient AVP; "Insufficient" would describe the opposite condition — diabetes insipidus — where AVP is lacking and the kidney cannot concentrate urine.
Option B: Option B is incorrect: the "I" stands for Inappropriate, not Intermittent; intermittent bursting AVP release is not the established pathophysiology of SIADH.
Option C: Option C is incorrect: "Inhibited" is the opposite of what occurs; in SIADH the AVP release is uninhibited — the normal suppressive feedback from low osmolality fails to switch it off.
Option D: Option D is incorrect: while drugs are a common cause of SIADH, the "I" stands for Inappropriate (the character of the release), not Induced (the mechanism of the cause); and pre-existing renal disease is not required.
6. Two vaptans are FDA-approved for treating hyponatremia in hospitalized patients: tolvaptan and conivaptan. A key practical difference between them is their route of administration. Which of the following correctly identifies this difference and its clinical consequence?
A) Tolvaptan is available only as an intravenous infusion for inpatient use; conivaptan is an oral tablet that can be continued after discharge for long-term outpatient management of SIADH.
B) Both tolvaptan and conivaptan are available in oral and intravenous formulations; the clinician selects based on the severity of hyponatremia — oral for mild (sodium 130–134 mEq/L) and intravenous for moderate-to-severe (sodium below 130 mEq/L).
C) Tolvaptan is an oral tablet, making it suitable for patients who can swallow medications; conivaptan is available only as an intravenous infusion, making it the appropriate choice when a patient cannot take oral medications — such as postoperative patients or those with a nasogastric tube on suction.
D) Tolvaptan is given as a subcutaneous injection once daily; conivaptan is given as an intravenous infusion; both require inpatient initiation but tolvaptan's subcutaneous route allows earlier transition to home care.
E) Both vaptans are oral; tolvaptan is taken once daily and conivaptan is taken twice daily; the difference in dosing frequency reflects their different receptor binding half-lives at the V2 receptor.
ANSWER: C
Rationale:
The route of administration is one of the most practically important differences between the two approved vaptans. Tolvaptan (Samsca) is an oral tablet taken once daily, starting at 15 mg with titration to 30 or 60 mg based on the sodium response at 24 hours. Because it requires the patient to swallow a tablet and absorb it through the gastrointestinal tract, it is only appropriate for patients who can take oral medications. Conivaptan (Vaprisol) is available exclusively as an intravenous formulation, administered as a 20 mg loading dose over 30 minutes followed by a continuous infusion; it is specifically designed for inpatient patients who cannot take oral medications — including postoperative patients, those with nasogastric tubes, or any patient in whom oral absorption is unreliable. This route difference has direct clinical consequences: a hospitalized patient who cannot swallow requires conivaptan, not tolvaptan; a patient who is alert and tolerating oral intake should receive tolvaptan rather than conivaptan, since tolvaptan avoids the hemodynamic risk of V1a blockade (hypotension) that conivaptan carries.
Option A: Option A is incorrect: the routes are reversed; tolvaptan is the oral agent and conivaptan is the intravenous agent; tolvaptan for hyponatremia is approved for inpatient use not exceeding 30 days and is not approved for indefinite outpatient management.
Option B: Option B is incorrect: conivaptan does not exist in an oral formulation; severity of hyponatremia does not determine route selection — route is determined by whether the patient can take oral medications.
Option D: Option D is incorrect: tolvaptan is an oral tablet, not a subcutaneous injection; subcutaneous administration is not an approved route for either vaptan.
Option E: Option E is incorrect: conivaptan is not an oral agent; it is intravenous only; describing both as oral is pharmacologically incorrect.
7. Desmopressin (also called DDAVP) is a synthetic drug derived from AVP with two specific structural changes that make it clinically more useful than natural AVP for certain indications. Which of the following best describes desmopressin and its key advantages over natural AVP?
A) Desmopressin is a synthetic analog of AVP that has been engineered to act only on V2 receptors (kidney, antidiuresis) with no meaningful activity at V1a receptors (blood vessels, vasoconstriction); it lasts several hours rather than minutes, making it practical for treating central diabetes insipidus (insufficient AVP from the pituitary) and for stimulating the release of clotting factors before surgery — all without the blood pressure effects that make natural AVP unsuitable for repeated outpatient use.
B) Desmopressin is a synthetic analog of AVP with enhanced V1a activity; it is used as a vasopressor in septic shock at lower doses than natural vasopressin because its greater receptor affinity requires less drug to achieve the same blood pressure response.
C) Desmopressin is an AVP receptor blocker (antagonist) similar to tolvaptan; it is used in SIADH when tolvaptan is unavailable because it competitively displaces AVP from V2 receptors and produces aquaresis by the same mechanism.
D) Desmopressin is identical in structure to natural AVP but is made synthetically to ensure pharmaceutical purity; its clinical properties are identical to natural AVP including vasopressor effects and antidiuresis, making it interchangeable with natural vasopressin for all indications.
E) Desmopressin is a partial agonist at both V1a and V2 receptors; it produces mild vasoconstriction and moderate antidiuresis simultaneously, making it useful when both a vasopressor and antidiuretic effect are needed at the same time, such as in post-surgical hypotension with concurrent diabetes insipidus.
ANSWER: A
Rationale:
Desmopressin (1-desamino-8-D-arginine vasopressin) was engineered with two specific structural modifications that together make it a far safer and more practical antidiuretic agent than natural AVP. First, deamination of the cysteine at position 1 removes the site where enzymes in the blood (aminopeptidases) normally break down the hormone; this extends the drug's duration of action from minutes (like natural AVP) to several hours. Second, substitution of D-arginine for the natural L-arginine at position 8 eliminates binding to V1a receptors on blood vessel walls — removing the vasopressor (blood pressure-raising) effect of natural AVP — while leaving V2 receptor binding intact and actually stronger than natural AVP. The result is a drug that concentrates urine effectively and triggers the release of clotting factors (vWF and factor VIII) from blood vessel storage sites, without raising blood pressure. This makes it safe for repeated use at home in children with bedwetting or adults with diabetes insipidus, and for pre-surgical use in patients with bleeding disorders.
Option B: Option B is incorrect: desmopressin has reduced V1a activity, not enhanced V1a activity; it is not used as a vasopressor; natural vasopressin (not desmopressin) is the AVP agent used in septic shock.
Option C: Option C is incorrect: desmopressin is an agonist (activates) V2 receptors, not a blocker; it is the pharmacological opposite of a vaptan; using desmopressin in SIADH would worsen hyponatremia by adding more antidiuretic drive.
Option D: Option D is incorrect: desmopressin is not structurally identical to natural AVP; the two specific modifications (deamination at position 1 and D-arginine at position 8) fundamentally change its half-life and receptor selectivity, making it pharmacologically distinct from natural vasopressin.
Option E: Option E is incorrect: desmopressin is not a partial agonist at V1a receptors; its D-arginine modification specifically eliminates meaningful V1a activity; it does not produce significant vasoconstriction at therapeutic doses.
8. A patient with chronically low sodium (hyponatremia present for more than 2 days) is being treated and the sodium rises very quickly — 20 mEq/L in a single day. Several days later the patient develops slurred speech, difficulty swallowing, and weakness in all four limbs. Brain imaging shows damage to a region of the brainstem called the pons. What is this complication called and why does rapid sodium correction cause it?
A) This is cerebral edema caused by the rapid rise in sodium drawing water into brain cells; the swelling is greatest in the pons because pontine neurons have the highest water content of any brain cells and are most susceptible to volume expansion.
B) This is called rebound hypernatremia syndrome; the brain damage occurs because the rapid rise in sodium above 135 mEq/L triggers abnormal sodium channel activation in pontine interneurons, producing excitotoxic injury similar to stroke.
C) This is a hypertensive encephalopathy; the rapid correction of hyponatremia raises blood pressure by restoring normal vascular tone, and the pons — which has the least autoregulatory capacity of any brain region — is most vulnerable to the pressure injury.
D) This is called osmotic demyelination syndrome (ODS); in chronic hyponatremia, brain cells have adapted to the low-sodium environment by exporting certain molecules (organic osmoles) to reduce cell swelling; when sodium is corrected too rapidly, the brain cells — now depleted of these protective molecules — lose water faster than they can compensate, damaging the myelin sheaths that insulate nerve fibers; the pons is especially vulnerable because of its dense myelin content and limited blood supply.
E) This is called central pontine hemorrhage; rapid sodium correction causes osmotic rupture of pontine capillaries because the sudden increase in plasma tonicity creates a pressure gradient that exceeds the structural tolerance of small pontine blood vessels.
ANSWER: D
Rationale:
Osmotic demyelination syndrome (ODS) — previously called central pontine myelinolysis when restricted to the pons — is the most feared complication of overly rapid correction of chronic hyponatremia. To understand why it happens, it helps to know what the brain does to protect itself when sodium has been low for more than 48 hours: brain cells respond to the swelling pressure of a hypo-osmolar environment by actively exporting small protective molecules called organic osmoles (substances like taurine and myoinositol) to reduce the osmotic gradient that would otherwise pull water into cells. This adaptation takes days to establish and days to reverse. When sodium is corrected rapidly, the fluid surrounding brain cells becomes relatively concentrated very quickly — but the cells still have low internal osmolality because their organic osmoles were exported. Water rushes out of the adapted brain cells, causing them to shrink and damaging the myelin sheaths (the insulating coating around nerve fibers). The pons — a brainstem region with particularly dense myelin and a compact blood supply that limits its ability to buffer rapid changes — is disproportionately affected. The resulting clinical syndrome includes dysarthria (slurred speech), dysphagia (difficulty swallowing), and quadriparesis (weakness in all four limbs). Prevention is the only real treatment: the safe correction target is 4 to 8 mEq/L per 24 hours, with an absolute ceiling of 10 to 12 mEq/L per 24 hours.
Option A: Option A is incorrect: ODS involves cellular dehydration (water leaving adapted brain cells when sodium rises rapidly), not cellular swelling; cerebral edema is the risk of the uncorrected hyponatremia itself, not of its correction.
Option B: Option B is incorrect: the complication is osmotic demyelination syndrome, not a sodium-channel-mediated excitotoxic injury; hypernatremia is a risk of vaptan overtreatment but is a separate complication from ODS, which results from the rate of sodium rise from any cause.
Option C: Option C is incorrect: ODS is not a hypertensive encephalopathy; sodium correction does not necessarily raise blood pressure in a clinically significant way, and the mechanism is osmotic and demyelinating, not pressure-related.
Option E: Option E is incorrect: ODS involves demyelination of nerve fibers, not hemorrhagic rupture of capillaries; osmotic demyelination is a well-characterized myelin injury, not a vascular rupture syndrome.
9. Desmopressin is used before surgery in patients with certain bleeding disorders to temporarily raise the levels of clotting proteins in the blood. It does this by triggering the release of stored clotting proteins from small storage organelles inside blood vessel cells. What are these storage organelles called, and what clotting proteins do they contain?
A) Platelet alpha-granules — storage organelles inside platelets (not blood vessel cells) containing fibrinogen, platelet factor 4, and P-selectin; desmopressin activates platelets directly through thrombin receptors to trigger alpha-granule release.
B) Weibel-Palade bodies — storage organelles inside the cells lining blood vessels (endothelial cells), containing vWF (von Willebrand factor — a protein that helps platelets stick to damaged vessel walls) and factor VIII (a clotting protein required for the coagulation cascade); desmopressin activates V2 receptors on endothelial cells, triggering these organelles to release their contents rapidly into the bloodstream.
C) Dense granules — storage organelles inside platelets containing ADP, serotonin, and calcium; desmopressin triggers dense granule release through V1a receptors on the platelet surface, amplifying platelet activation and indirectly raising vWF levels through platelet-endothelial crosstalk.
D) Azurophilic granules — storage organelles inside neutrophils containing elastase and myeloperoxidase; desmopressin triggers their release to promote fibrin clot stability by generating an oxidative microenvironment at the site of vascular injury.
E) Secretory lysosomes — storage organelles inside endothelial cells containing both clotting factors and vasoactive substances; desmopressin triggers their release through a calcium-dependent mechanism that bypasses the V2 receptor and operates through direct membrane depolarization.
ANSWER: B
Rationale:
Weibel-Palade bodies are elongated, rod-shaped storage organelles found exclusively in vascular endothelial cells — the cells that line the inside of blood vessels. They are named after the researchers who first described them in 1964. Their primary cargo is vWF (von Willebrand factor), a large multimeric protein that acts as a bridge between damaged blood vessel walls and platelets, enabling platelet adhesion at sites of injury; they also contain factor VIII (a clotting factor required for the intrinsic coagulation cascade that generates thrombin). When desmopressin binds V2 receptors on endothelial cells, it activates the same cyclic AMP/protein kinase A signaling cascade used in kidney collecting duct cells — but in endothelial cells this cascade triggers exocytosis (outward release) of Weibel-Palade bodies, rapidly flooding the bloodstream with vWF multimers and factor VIII. A single IV dose of desmopressin (0.3 mcg/kg) typically raises plasma vWF and factor VIII levels two- to fivefold within 30 to 60 minutes. This is why the same V2 receptor that concentrates urine in the kidney also produces hemostasis in endothelial cells — the same signaling pathway drives two completely different biological outcomes depending on the cell type's contents.
Option A: Option A is incorrect: alpha-granules are in platelets, not endothelial cells; desmopressin does not act through thrombin receptors (PAR-1) on platelets; the hemostatic release triggered by desmopressin is from Weibel-Palade bodies in endothelial cells, not platelet granules.
Option C: Option C is incorrect: dense granules are in platelets (containing ADP and serotonin), not endothelial cells; desmopressin does not trigger dense granule release through V1a receptors on platelets; the hemostatic mechanism is endothelial V2 receptor-mediated.
Option D: Option D is incorrect: azurophilic granules are in neutrophils and contain antimicrobial enzymes; they have no role in hemostasis, and desmopressin has no established mechanism involving neutrophil granule release.
Option E: Option E is incorrect: secretory lysosomes are not the established name for the desmopressin-responsive endothelial storage compartment; Weibel-Palade bodies are the specific organelles; the release mechanism is V2 receptor-dependent cAMP/PKA signaling, not calcium-dependent membrane depolarization independent of V2 receptors.
10. A 38-year-old man has been vomiting and unable to eat or drink for 5 days. He presents dehydrated with low blood pressure, rapid heart rate, and dry mucous membranes. His sodium is 118 mEq/L. A medical student suggests starting tolvaptan to correct the low sodium. Why is tolvaptan the wrong choice in this patient, and what is the correct treatment?
A) Tolvaptan is the wrong choice because it only works in patients with sodium below 120 mEq/L; since this patient's sodium is 118 mEq/L and tolvaptan requires sodium below 115 mEq/L to be effective, the drug would not produce meaningful aquaresis at this level.
B) Tolvaptan is the wrong choice because it requires simultaneous fluid restriction to be effective; this patient cannot tolerate fluid restriction because of his dehydrated state, making the drug combination impossible.
C) Tolvaptan is the wrong choice because it can only be used in patients with confirmed SIADH from a malignant tumor; other causes of hyponatremia require different agents.
D) Tolvaptan is the wrong choice because it has a black box warning for use in dehydrated patients that prohibits its use until blood pressure is normalized by other means first.
E) Tolvaptan is the wrong choice because this patient's low sodium is caused by dehydration (volume depletion), not by excess AVP; his body is correctly releasing AVP to try to retain water and protect blood pressure — if tolvaptan forces the kidney to lose more free water on top of the existing dehydration, his blood pressure will drop further; the correct treatment is intravenous saline to replace the lost fluid volume, which will naturally turn off the AVP signal and allow the sodium to correct itself.
ANSWER: E
Rationale:
Understanding why vaptans are contraindicated in volume depletion requires connecting two concepts introduced earlier: (1) AVP is released not only when plasma osmolality is high but also when blood volume/pressure is low (the hemodynamic trigger); and (2) vaptans produce aquaresis — electrolyte-free water loss from the kidney. In this patient, the low sodium is driven by dehydration: volume loss has activated baroreceptors (pressure sensors), which have triggered AVP release as a survival response — the body is trying to hold onto water to maintain blood pressure. The AVP release here is physiologically appropriate, not inappropriate. Administering tolvaptan would block the kidney's V2 receptors and force excretion of more free water at exactly the moment when the body needs to retain fluid — worsening the hemodynamic state and potentially causing circulatory collapse. The correct treatment is isotonic saline (normal saline or Ringer's lactate): replacing the lost fluid volume restores blood pressure, deactivates the baroreceptor-AVP signal, and the kidney spontaneously stops concentrating urine and begins excreting the excess free water — correcting the sodium without any AVP-blocking drug. The low urine sodium that characterizes volume depletion (the kidney desperately holding onto salt) is the biochemical clue that distinguishes this from SIADH and should redirect the clinician to saline, not a vaptan.
Option A: Option A is incorrect: tolvaptan has no sodium threshold below which it becomes effective; it is approved for sodium below 135 mEq/L regardless of the specific level; the objection to its use here is the volume-depleted mechanism, not the sodium value.
Option B: Option B is incorrect: tolvaptan is specifically used without fluid restriction — fluid restriction is contraindicated alongside vaptans; the reason to avoid tolvaptan here is the hemodynamic risk of aquaresis in a dehydrated patient.
Option C: Option C is incorrect: tolvaptan is approved for both euvolemic and hypervolemic hyponatremia from any cause — not restricted to malignancy-associated SIADH.
Option D: Option D is incorrect: there is no black box warning that prohibits tolvaptan use based on blood pressure; the absolute contraindication is inability to perceive or respond to thirst, and use in hypovolemic hyponatremia (which is described in the prescribing information as a contraindication), not a blood-pressure threshold.
11. A resident starts a patient on tolvaptan for SIADH and also writes an order restricting the patient's fluid intake to 800 mL per day, reasoning that combining two water-reducing strategies will correct the sodium faster. The attending physician cancels the fluid restriction order immediately. Why is combining tolvaptan with fluid restriction dangerous?
A) Fluid restriction reduces sodium intake alongside water intake, counteracting tolvaptan's sodium-raising effect and making the drug ineffective — the combination produces no net change in serum sodium.
B) Fluid restriction activates the renin-angiotensin-aldosterone system, which causes sodium retention and counteracts the aquaresis produced by tolvaptan, leading to paradoxical worsening of hyponatremia.
C) Tolvaptan causes the kidney to continuously lose free water regardless of how much the patient drinks; the only way to prevent the sodium from rising too quickly is for the patient to drink freely when thirsty — if fluid is restricted, there is nothing to buffer the ongoing water loss, and the sodium can rise dangerously fast, risking the brain damage (osmotic demyelination syndrome) that comes with overly rapid correction.
D) Fluid restriction lowers blood pressure by reducing intravascular volume; combined with tolvaptan's V1a-blocking effect, the two produce additive hypotension that can cause circulatory collapse in hospitalized patients.
E) Fluid restriction is safe to combine with tolvaptan for the first 24 hours but must be discontinued once the sodium reaches 128 mEq/L; the attending's concern was that the fluid restriction was started too early in the correction process.
ANSWER: C
Rationale:
The safety of tolvaptan depends on a physiological feedback loop that the prescribing team must actively protect. When tolvaptan blocks V2 receptors, the kidney continuously excretes electrolyte-free water (aquaresis), raising serum sodium. The rate at which sodium rises depends on how much of that lost water the patient replaces by drinking. When plasma osmolality rises — because sodium is going up — the brain's thirst center (osmoreceptors in the hypothalamus) detects this and triggers thirst. If the patient responds to thirst by drinking water, the intake partially offsets the losses and slows the rate of sodium correction, keeping it within the safe ceiling of 10 to 12 mEq/L per 24 hours. If fluid intake is restricted to 800 mL per day, the patient cannot respond to thirst by drinking enough to buffer the aquaresis — the sodium keeps rising at the unchecked aquaretic rate, which can easily drive correction above the ceiling and into the danger zone for osmotic demyelination syndrome. This is why the prescribing information for tolvaptan explicitly states that fluid restriction must not be co-administered during vaptan therapy. The mandatory instruction to patients on vaptans is to drink freely whenever they feel thirsty — the thirst drive is the built-in safety valve, and restricting fluid removes it.
Option A: Option A is incorrect: fluid restriction does not reduce sodium intake (fluids contain water, not primarily sodium); the concern is about free-water restriction removing the rate buffer, not about sodium delivery.
Option B: Option B is incorrect: the renin-angiotensin-aldosterone axis is not the mechanism here; aldosterone activation would retain sodium and water, which might actually partially offset the aquaresis; the danger is the removal of the thirst-driven free-water buffer, not aldosterone activation.
Option D: Option D is incorrect: tolvaptan is a selective V2 antagonist with no meaningful V1a-blocking activity; it does not lower blood pressure through V1a blockade — that is a property of conivaptan; the combination danger described here is rate of sodium rise, not hypotension.
Option E: Option E is incorrect: there is no approved combination window during which fluid restriction alongside tolvaptan is safe; the contraindication is absolute from the moment tolvaptan is started through the entire course of therapy.
12. There are two main types of diabetes insipidus (DI) — a condition in which the kidneys produce enormous volumes of dilute urine. In central DI, the problem is that the pituitary gland does not release enough AVP. In nephrogenic DI (nephrogenic — arising in the kidney), the pituitary releases AVP normally, but the kidney does not respond to it. Desmopressin effectively treats central DI but not nephrogenic DI. Why?
A) In central DI, desmopressin replaces the missing AVP signal and successfully activates the V2 receptors that are still working normally in the kidney; in nephrogenic DI, the V2 receptors themselves are non-functional (or the downstream signaling machinery is broken) due to a genetic defect — no matter how much desmopressin is given, it cannot generate the cellular response needed to insert AQP2 water channels, so urine concentration cannot be achieved.
B) In central DI, desmopressin works because it stimulates the pituitary to produce more natural AVP, compensating for the secretion deficit; in nephrogenic DI, desmopressin cannot stimulate pituitary AVP production because the defect is downstream in the kidney.
C) In central DI, desmopressin reaches the kidney at higher concentrations because it bypasses hepatic first-pass metabolism; in nephrogenic DI, the kidney's increased blood flow destroys desmopressin before it can bind receptors, making the drug pharmacokinetically ineffective at the target organ.
D) Both forms respond to desmopressin equally, but nephrogenic DI requires tenfold higher doses than central DI because the mutant V2 receptor has reduced drug affinity rather than complete loss of function; the standard dose is simply too low for nephrogenic DI.
E) In nephrogenic DI, desmopressin is partially effective at V1a receptors in the kidney, providing some degree of water retention through vasoconstriction of renal arterioles; it fails to fully correct the polyuria because V1a-mediated water retention is less efficient than V2-mediated AQP2 insertion.
ANSWER: A
Rationale:
The reason desmopressin works in central DI but not nephrogenic DI follows directly from where the defect lies in each condition. In central DI, the problem is insufficient AVP signal from the pituitary — the kidney's V2 receptors and all their downstream machinery are perfectly intact and waiting to respond. Desmopressin steps in as a replacement signal: it binds the functional V2 receptors, activates the cAMP pathway, triggers AQP2 vesicle insertion, and concentrates urine normally. In nephrogenic DI, the defect is in the kidney itself — most commonly a loss-of-function mutation in the AVPR2 gene (which encodes the V2 receptor), which either prevents the receptor from reaching the cell surface properly or impairs its ability to activate the Gs protein when a drug binds it. Because the receptor or its downstream cascade is non-functional, even large amounts of desmopressin cannot transmit the "concentrate urine" signal — the signaling chain is broken at the first step. Some nephrogenic DI cases involve mutations in the AQP2 gene itself (the water channel), in which case the V2 receptor might function normally but there are no working water channels to insert; desmopressin again produces no antidiuresis. The clinical test that distinguishes the two: if desmopressin increases urine osmolality, it is central DI; if it has no effect, it is nephrogenic DI.
Option B: Option B is incorrect: desmopressin does not stimulate pituitary AVP production; it is a direct-acting V2 receptor agonist that bypasses the pituitary entirely; its mechanism is pharmacological replacement of the hormone at the target organ, not stimulation of endogenous production.
Option C: Option C is incorrect: desmopressin is not destroyed in the kidney in nephrogenic DI; the drug reaches V2 receptors normally — the problem is that the receptors cannot transduce the signal, not that the drug fails to arrive.
Option D: Option D is incorrect: most clinically significant nephrogenic DI from AVPR2 mutations causes complete or near-complete loss of V2 receptor function, not merely reduced affinity; suprapherapeutic desmopressin doses do not restore meaningful antidiuresis in these patients.
Option E: Option E is incorrect: desmopressin has essentially no V1a activity at therapeutic doses — V1a activity was specifically eliminated by the D-arginine modification at position 8; there is no V1a-mediated renal water retention mechanism to partially compensate.
13. Tolvaptan is broken down primarily by a liver enzyme called CYP3A4 (an enzyme that metabolizes a large number of medications). A patient stabilized on tolvaptan 15 mg daily for SIADH is started on a new antifungal drug that strongly inhibits CYP3A4 — meaning it blocks this enzyme from working. What is the most likely consequence of this drug combination?
A) The antifungal will have no effect on tolvaptan levels because tolvaptan is excreted by the kidneys unchanged, not metabolized by liver enzymes; CYP3A4 inhibition is irrelevant to tolvaptan pharmacokinetics.
B) Blocking CYP3A4 will cause tolvaptan to be metabolized faster, reducing its plasma levels below therapeutic threshold and causing the patient's sodium to fall back toward the hyponatremic range.
C) Blocking CYP3A4 will cause tolvaptan to accumulate in the liver specifically, producing hepatotoxicity without significantly changing the amount of tolvaptan reaching the kidney's V2 receptors.
D) Blocking CYP3A4 will slow tolvaptan's breakdown, causing tolvaptan to accumulate in the blood at higher concentrations than normal; with more tolvaptan reaching the kidney, V2 receptors will be blocked more completely and for longer, producing stronger and more prolonged aquaresis — raising the risk that serum sodium rises too quickly and crosses the safe correction ceiling.
E) Blocking CYP3A4 will convert tolvaptan to an active metabolite with V1a agonist activity, paradoxically causing vasoconstriction and hypertension as tolvaptan accumulates; sodium handling will be unaffected.
ANSWER: D
Rationale:
Tolvaptan is primarily eliminated through CYP3A4-mediated metabolism in the liver and intestinal wall, with the resulting metabolites excreted mainly in feces. When a strong CYP3A4 inhibitor (such as certain antifungal drugs like ketoconazole, itraconazole, or voriconazole, or antibiotics like clarithromycin) is added, the enzyme responsible for breaking down tolvaptan is blocked — tolvaptan cannot be metabolized at its normal rate, so it accumulates in the bloodstream at higher concentrations than the prescribed dose was designed to produce. Higher plasma tolvaptan levels mean more complete and more prolonged V2 receptor blockade in the kidney, producing a stronger and longer-lasting aquaresis than intended. If the patient cannot drink enough free water to keep pace with the increased rate of sodium correction, the serum sodium may rise beyond the safe ceiling of 10 to 12 mEq/L per 24 hours — risking osmotic demyelination syndrome. This interaction requires dose reduction or careful monitoring (with more frequent sodium checks) when potent CYP3A4 inhibitors must be co-administered with tolvaptan.
Option A: Option A is incorrect: tolvaptan is not renally excreted unchanged; it is predominantly metabolized by CYP3A4 in the liver with fecal excretion of metabolites; CYP3A4 inhibition is highly relevant to tolvaptan pharmacokinetics.
Option B: Option B is incorrect: blocking an enzyme slows drug metabolism and increases plasma levels — it does not accelerate metabolism; option B has the direction of the effect reversed.
Option C: Option C is incorrect: CYP3A4 inhibition does not cause selective accumulation in the liver; tolvaptan circulates systemically, and higher plasma concentrations mean more drug reaching all V2 receptors including those in the kidney; the consequence is enhanced pharmacological effect, not organ-specific toxicity (the hepatotoxicity concern for tolvaptan applies specifically to the ADPKD indication at higher doses, not from CYP3A4 inhibitor drug interactions at hyponatremia doses).
Option E: Option E is incorrect: tolvaptan metabolites do not have V1a agonist activity; tolvaptan is a V2 receptor antagonist and its metabolites do not produce vasoconstriction; there is no pharmacological basis for this mechanism.
14. Desmopressin is a useful hemostatic agent in type 1 von Willebrand disease (a condition where vWF — a clotting protein — is present in reduced amounts but works normally). However, desmopressin is specifically contraindicated in type 2B von Willebrand disease, where a genetic change makes vWF too "sticky" — causing it to grab onto platelets even when there is no bleeding. What happens when desmopressin is given to a type 2B patient, and why does this make it harmful?
A) In type 2B vWD, the Weibel-Palade bodies have been permanently emptied by the overactive vWF production; desmopressin cannot trigger any release because the storage pool is depleted, making the drug ineffective but not harmful.
B) In type 2B vWD, the vWF stored in Weibel-Palade bodies is structurally abnormal — it grabs onto platelets too readily; when desmopressin triggers a large release of this abnormal vWF into the bloodstream, the vWF immediately binds large numbers of circulating platelets, causing platelet clumping and a rapid drop in platelet count (thrombocytopenia); instead of improving hemostasis, desmopressin makes it worse.
C) In type 2B vWD, the V2 receptors on endothelial cells are constitutively active due to the same genetic mutation; desmopressin over-activates an already hyperactive receptor, producing 20 to 30 times the normal amount of vWF release and causing vascular occlusion rather than hemostasis.
D) In type 2B vWD, desmopressin activates V1a receptors rather than V2 receptors because the genetic mutation shifts the endothelial receptor preference; V1a activation produces vasoconstriction rather than vWF release, worsening local ischemia at the site of bleeding.
E) In type 2B vWD, desmopressin correctly releases normal vWF from Weibel-Palade bodies, but the abnormal vWF already circulating blocks the platelet receptor (GPIb) that normal vWF needs to bind — so the released normal vWF finds all receptor sites occupied and produces no hemostatic benefit.
ANSWER: B
Rationale:
This question connects the Weibel-Palade body release mechanism (established in Q9) to a clinical contraindication. In type 1 vWD, the vWF stored in Weibel-Palade bodies is structurally normal — there is simply less of it. Desmopressin releases the stored normal vWF into the bloodstream, raising levels enough for minor hemostasis. In type 2B vWD, a genetic mutation in the vWF gene produces a form of vWF that has an abnormally strong affinity for the GPIb receptor on platelet surfaces. This abnormal vWF spontaneously grabs platelets even when there is no injury — causing mild chronic thrombocytopenia (low platelet count) at baseline. When desmopressin is given to a type 2B patient, it triggers the same Weibel-Palade body release mechanism as in other patients — releasing a large bolus of this structurally abnormal, platelet-grabbing vWF into the circulation. The abnormal vWF then binds platelets massively and rapidly, causing widespread platelet clumping and an acute further drop in platelet count. The result is paradoxically worse hemostasis — more abnormal vWF + fewer available platelets — rather than improved hemostasis. For this reason, desmopressin is absolutely contraindicated in type 2B vWD; these patients require vWF concentrate (which provides structurally normal exogenous vWF) for hemostatic coverage.
Option A: Option A is incorrect: type 2B vWD patients do have vWF stored in Weibel-Palade bodies (the storage pool is intact); the problem is not depletion but the abnormal structure of the stored protein.
Option C: Option C is incorrect: the V2 receptors on endothelial cells are not affected by the vWF gene mutation; the mutation is in the vWF protein gene (VWF), not the receptor gene (AVPR2); the receptor responds to desmopressin normally — the problem is the cargo (abnormal vWF), not the signal.
Option D: Option D is incorrect: desmopressin acts through V2 receptors on endothelial cells to release vWF; it does not shift to V1a receptor activation in type 2B vWD; the mechanism of harm is the released abnormal vWF binding platelets, not vasoconstriction.
Option E: Option E is incorrect: in type 2B vWD, the Weibel-Palade body vWF is itself abnormal (not a mixture of normal and abnormal vWF); the stored vWF carries the same gain-of-function mutation as the circulating vWF; the mechanism of harm is active platelet aggregation by the released abnormal vWF, not competitive receptor blocking.
15. A patient with SIADH caused by a lung tumor is treated with tolvaptan for 30 days. Her sodium normalizes to 134 mEq/L. Tolvaptan is then discontinued. Within one week, her sodium falls back to 118 mEq/L — exactly where it was before treatment. What does this outcome tell us about how tolvaptan works, and what clinical lesson does it illustrate?
A) The sodium relapse means tolvaptan caused permanent damage to the kidney's water-handling ability — it temporarily blocked the V2 receptors so forcefully that the receptors cannot function normally once the drug is removed.
B) The sodium relapse confirms that tolvaptan was the wrong drug for this patient; SIADH from a lung tumor requires chemotherapy first, and sodium-correcting drugs like tolvaptan should never be used until the tumor has been treated.
C) The sodium relapse indicates tolvaptan resistance — the tumor has produced a variant of AVP that is immune to tolvaptan blockade; a higher dose or switch to conivaptan should be tried on reinitiation.
D) The sodium relapse is expected and confirms the dose was too low; with a higher dose, the receptor blockade would have lasted longer after the drug was discontinued, preventing the relapse.
E) The sodium relapse confirms that tolvaptan corrects the low-sodium consequence of SIADH only while the drug is present — it does not treat the underlying cause (the tumor still secreting AVP); once tolvaptan is cleared from the body, the V2 receptors become unblocked, AVP from the tumor resumes driving water retention, and the sodium falls again; the clinical lesson is that durable correction of SIADH requires treating the underlying cause, not just blocking the AVP signal indefinitely.
ANSWER: E
Rationale:
This outcome directly demonstrates the pharmacodynamic nature of tolvaptan's mechanism. Tolvaptan is a competitive, reversible V2 receptor antagonist — it occupies V2 receptors as long as sufficient drug concentrations are present in the bloodstream, blocking AVP from activating them. The moment tolvaptan is cleared (with a half-life of 5 to 12 hours, plasma levels fall substantially within a day or two of stopping), the V2 receptors are no longer blocked and become available to AVP again. In this patient, the tumor is still secreting AVP-like peptides continuously — that has not changed. As soon as tolvaptan clears, the tumor's AVP drives AQP2 channel insertion once more, water reabsorption resumes, and sodium falls back toward the level determined by the underlying disease, not the drug. The clinical lesson is important: tolvaptan manages hyponatremia but does not cure it. For durable correction, the underlying cause must be addressed — in this patient, the tumor must be treated (with chemotherapy, radiation, or surgery). This was directly demonstrated in the SALT-1 and SALT-2 clinical trials, which showed that sodium returned to pre-treatment levels within 7 days of stopping tolvaptan. Tolvaptan is therefore a bridge therapy — useful for stabilizing sodium while a definitive treatment for the underlying SIADH cause is implemented.
Option A: Option A is incorrect: tolvaptan causes no permanent kidney damage; V2 receptors recover completely after tolvaptan is cleared; the competitive blockade is fully reversible.
Option B: Option B is incorrect: tolvaptan is entirely appropriate as a bridge to control sodium while the tumor is being addressed; there is no clinical rule prohibiting sodium correction until after chemotherapy is initiated.
Option C: Option C is incorrect: tolvaptan resistance from a tumor-derived AVP variant is not a recognized clinical phenomenon; the relapse is mechanistically expected from a reversible competitive antagonist, not evidence of pharmacological failure.
Option D: Option D is incorrect: the relapse is not dose-dependent; no dose of tolvaptan produces receptor blockade lasting more than a few days after the drug is cleared; extending the duration of blockade is not achievable by dose escalation alone.
16. A hospitalized patient with low sodium is being treated with conivaptan, which blocks both V1a and V2 receptors. After the first infusion, the patient's blood pressure drops significantly and the nursing staff calls for assistance. This blood pressure drop would not be expected with tolvaptan, which blocks only V2 receptors. Why does blocking V1a receptors lower blood pressure?
A) V1a blockade in the kidney reduces sodium reabsorption, causing the body to lose salt and water; the resulting volume depletion lowers blood pressure in the same way that dehydration does.
B) V1a blockade in the heart reduces the strength of cardiac contraction by interfering with calcium handling in cardiac muscle cells, reducing cardiac output and causing the blood pressure drop.
C) V1a receptors on blood vessel walls normally allow AVP to cause vasoconstriction — tightening blood vessels and maintaining blood pressure; when conivaptan blocks these V1a receptors, AVP can no longer constrict the vessels, vasomotor tone decreases, and blood vessels relax, lowering blood pressure — an effect that is especially significant in critically ill patients where AVP is already elevated and contributing meaningfully to blood pressure maintenance.
D) V1a receptors are located on baroreceptors in the carotid sinus; blocking them impairs the brain's ability to detect and respond to low blood pressure, preventing the normal compensatory rise in heart rate and vascular resistance that would otherwise prevent hypotension.
E) V1a blockade prevents AVP from stimulating aldosterone release from the adrenal gland; without aldosterone, the kidney loses sodium, extracellular fluid volume falls, and blood pressure drops over several days as the sodium deficit accumulates.
ANSWER: C
Rationale:
This question connects the V1a receptor location and function (established in Q3 of this set) to the clinical consequence of blocking it. In Q3 we established that V1a receptors are on blood vessel walls (vascular smooth muscle) and that their activation by AVP causes vasoconstriction. When conivaptan blocks V1a receptors, it prevents AVP from maintaining this vascular tone. Blood vessels that were being actively constricted by AVP-V1a signaling can now relax — producing vasodilation and a fall in blood pressure. This effect is particularly significant in ICU patients, postoperative patients, and anyone with already elevated circulating AVP levels (from hemodynamic stress, volume shifts, or disease), because in these patients V1a-mediated vasoconstriction is actively contributing to blood pressure maintenance. Removing it acutely can produce a clinically significant blood pressure drop. Tolvaptan avoids this complication because it blocks only V2 receptors (kidney, water handling) and has no meaningful V1a activity — it does not disturb vascular tone. This is one of the key reasons tolvaptan is preferred over conivaptan when the patient can take oral medications: same aquaresis, without the hemodynamic risk.
Option A: Option A is incorrect: V1a receptors are not on renal tubular sodium transporters; V1a blockade does not directly cause sodium or volume loss; aquaresis (free-water loss without sodium loss) is a V2-mediated event, not V1a-mediated.
Option B: Option B is incorrect: V1a receptors are not established as clinically significant calcium-handling receptors in cardiac muscle; the hypotension from conivaptan is vascular (reduced peripheral resistance from vasodilation), not cardiogenic (reduced cardiac output from myocardial depression).
Option D: Option D is incorrect: baroreceptors in the carotid sinus detect stretch from blood pressure mechanically — they are not GPCRs activated by AVP; V1a receptor blockade does not impair baroreceptor function or blunt the reflex response to hypotension.
Option E: Option E is incorrect: aldosterone is regulated primarily by angiotensin II (through AT1 receptors) and plasma potassium — not by AVP through V1a receptors; clinically significant aldosterone suppression from V1a blockade is not an established mechanism of conivaptan-induced hypotension, and aldosterone-mediated sodium loss develops over days, not as an acute hypotensive event after a single infusion.
17. A 51-year-old woman has a serum sodium of 120 mEq/L. Her urine sodium is 9 mEq/L (very low — normal is above 20 mEq/L when eating normally). She has been having severe diarrhea for 4 days and appears clinically dehydrated. A colleague suggests starting tolvaptan. Using what you have learned about SIADH and hypovolemic hyponatremia, which response is correct?
A) The urine sodium of 9 mEq/L means the kidney is holding onto sodium as tightly as it can — this is the body's response to volume depletion, not SIADH; in SIADH the urine sodium is high (above 40 mEq/L) because the body senses adequate volume; tolvaptan would make this patient worse by forcing more water loss on top of existing dehydration; the correct treatment is intravenous saline to replace lost fluid.
B) The urine sodium of 9 mEq/L is consistent with SIADH because the kidney is retaining sodium appropriately in the setting of low serum sodium; this confirms that AVP is being released inappropriately and tolvaptan is the correct treatment.
C) The urine sodium value is not diagnostically useful; the decision between tolvaptan and saline should be based solely on the serum sodium level — for sodium below 125 mEq/L, tolvaptan is always preferred over saline regardless of the underlying mechanism.
D) The low urine sodium confirms nephrogenic diabetes insipidus, in which the kidney cannot concentrate urine due to V2 receptor dysfunction; tolvaptan is ineffective and desmopressin should be tried first.
E) The urine sodium of 9 mEq/L indicates that the patient has aldosterone deficiency — the kidneys should be retaining sodium via aldosterone but are failing to do so; fludrocortisone (a synthetic aldosterone) should be administered before considering any vaptan.
ANSWER: A
Rationale:
This bridge question applies the urine sodium concept from Q5 and the hypovolemic contraindication from Q10 to a scenario requiring real clinical discrimination. In Q5, we established that SIADH produces a urine sodium above 40 mEq/L because the volume receptors sense euvolemia and do not trigger sodium conservation. In Q10, we established that vaptans are contraindicated in volume-depleted patients because aquaresis worsens hemodynamic compromise. Now those two concepts must be combined: a urine sodium of 9 mEq/L tells us the kidney is in maximum sodium-conservation mode — it is holding onto every sodium ion it can, which is exactly what happens in volume depletion (triggered by aldosterone and sympathetic nerve activity). This pattern is incompatible with SIADH, where the kidney would be freely excreting sodium despite low plasma levels. The clinical picture reinforces this: 4 days of diarrhea causing dehydration is a classic setup for hypovolemic hyponatremia. The AVP elevated by baroreceptor activation is causing water retention appropriately — this is not inappropriate (SIADH). Tolvaptan would force the kidney to lose free water, reducing intravascular volume further on top of existing dehydration. Saline replaces the lost volume, turns off the baroreceptor AVP drive, and allows the kidney to spontaneously correct the sodium.
Option B: Option B is incorrect: a urine sodium of 9 mEq/L is opposite to the SIADH pattern; it confirms volume depletion, not SIADH; the sentence "kidney is retaining sodium appropriately" is correct as stated but leads to the wrong conclusion — appropriate sodium retention means the mechanism is volume depletion, not SIADH.
Option C: Option C is incorrect: urine sodium is one of the most diagnostically useful measurements in hyponatremia; treatment selection cannot be based on serum sodium level alone without determining the underlying mechanism; vaptans are never preferred over saline in volume depletion regardless of the sodium value.
Option D: Option D is incorrect: low urine sodium does not indicate nephrogenic DI; nephrogenic DI presents with large volumes of dilute urine and hypernatremia (high sodium), the opposite of this patient's presentation; the clinical picture here is volume depletion with hyponatremia.
Option E: Option E is incorrect: a urine sodium of 9 mEq/L in this clinical context reflects normal aldosterone activity — the kidneys are maximally retaining sodium as they should in volume depletion; this is not a sign of aldosterone deficiency.
18. Two patients each have a low sodium level and fluid overload from heart failure. Patient A is treated with tolvaptan (blocks V2 receptors, produces aquaresis). Patient B is treated with furosemide (a loop diuretic that blocks a sodium-potassium-chloride transporter in the kidney, forcing the kidney to excrete sodium, potassium, and water together). After treatment, which of the following best predicts how their electrolyte profiles will differ?
A) Patient A will develop low potassium and low sodium because aquaresis removes both water and electrolytes equally; Patient B will develop high sodium because the sodium lost in the urine is replaced by the body's sodium stores, concentrating the remaining blood sodium.
B) Both patients will have identical electrolyte changes because any drug that increases urine output must remove proportional amounts of all electrolytes from the filtered fluid; the kidney cannot selectively remove water without electrolytes.
C) Patient A will develop high potassium because blocking V2 receptors secondarily stimulates aldosterone, which drives potassium secretion into the urine; Patient B will develop low sodium because furosemide directly activates sodium excretion pumps in the collecting duct.
D) Patient A (tolvaptan) will lose primarily free water without losing sodium or potassium — the sodium in the blood becomes more concentrated (sodium rises) without depleting electrolytes; Patient B (furosemide) will lose sodium, potassium, and water in the urine — the sodium may not rise as reliably and potassium will fall, often requiring supplementation.
E) Both patients will lose equal amounts of sodium, and the only difference will be urine volume — Patient A will produce larger volumes of very dilute urine while Patient B will produce smaller volumes of more concentrated urine; the sodium effect will be identical.
ANSWER: D
Rationale:
This bridge question applies the aquaresis concept from Q4 to a comparative prediction. In Q4 we established that vaptans produce aquaresis — excretion of electrolyte-free water — because blocking V2 receptors prevents AQP2 insertion and the dilute tubular fluid (already largely stripped of electrolytes by upstream nephron segments) passes through into the urine without further electrolyte extraction. The urine produced by tolvaptan is hypotonic and electrolyte-poor. The body's electrolytes (sodium, potassium, chloride) are not significantly lost in this urine — only water is lost. The result: blood electrolyte concentrations rise because the same amount of electrolytes are now dissolved in less water. Sodium goes up, and potassium remains relatively stable. Furosemide works completely differently: it blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle — a part of the kidney that is actively reabsorbing large amounts of sodium, potassium, chloride, and magnesium. Every liter of furosemide-induced urine carries substantial quantities of these electrolytes out of the body. The result: potassium falls (often requiring supplementation), magnesium falls, sodium correction is less reliable (because some sodium is also lost), and volume falls. These are fundamentally different pharmacological mechanisms producing fundamentally different metabolic consequences — and this distinction matters enormously in clinical practice when choosing between the two drugs in hyponatremia.
Option A: Option A is incorrect: aquaresis does not remove electrolytes equally with water; it specifically removes electrolyte-free water; Patient A will not develop low potassium from tolvaptan.
Option B: Option B is incorrect: the kidney absolutely can remove water selectively without removing proportional electrolytes — this is precisely what aquaresis is; the collecting duct, when AQP2 channels are blocked, allows dilute electrolyte-poor filtrate to pass as urine.
Option C: Option C is incorrect: tolvaptan does not stimulate aldosterone; blocking V2 receptors has no established direct effect on aldosterone secretion; furosemide does not activate collecting duct sodium excretion pumps.
Option E: Option E is incorrect: the electrolyte effects of the two drugs are not identical; tolvaptan preserves sodium and potassium while furosemide depletes them — this is a pharmacologically fundamental difference, not merely a urine volume difference.
19. A patient with chronic SIADH has a sodium of 114 mEq/L when treatment begins. Using the safe correction principles described in Q8, which of the following sodium trajectories over the next 24 hours represents a dangerous rate of correction?
A) Sodium rises from 114 to 120 mEq/L in 24 hours — a rise of 6 mEq/L. The team is satisfied and continues the current therapy at the same rate.
B) Sodium rises from 114 to 130 mEq/L in 24 hours — a rise of 16 mEq/L. The team considers this excellent progress because the patient feels better and the sodium is now near normal range.
C) Sodium rises from 114 to 121 mEq/L in 24 hours — a rise of 7 mEq/L. The team monitors closely and plans to check sodium again in 12 hours.
D) Sodium rises from 114 to 122 mEq/L in 24 hours — a rise of 8 mEq/L. The team notes this is at the upper end of the target range and plans careful monitoring.
E) Sodium rises from 114 to 119 mEq/L in 24 hours — a rise of 5 mEq/L. The team continues therapy with sodium checks twice daily.
ANSWER: B
Rationale:
This bridge question applies the ODS safe-correction-rate concept from Q8 directly to numerical scenarios. In Q8 we established that the safe correction target for chronic hyponatremia is 4 to 8 mEq/L per 24 hours, with an absolute ceiling of 10 to 12 mEq/L per 24 hours and no more than 18 mEq/L per 48 hours. A rise of 16 mEq/L in 24 hours (option B, from 114 to 130) substantially exceeds the absolute ceiling of 12 mEq/L and puts the patient at significant risk of osmotic demyelination syndrome. The fact that the patient feels better and the sodium is now closer to normal does not make this safe — ODS symptoms do not appear immediately; they emerge 2 to 6 days after the rapid correction, by which time the demyelinating injury is already underway. The team's satisfaction with the apparent clinical progress is a dangerous cognitive trap: in hyponatremia management, feeling better immediately and being safe are not the same thing. Options A (6 mEq/L), C (7 mEq/L), D (8 mEq/L), and E (5 mEq/L) are all within the target range of 4 to 8 mEq/L per 24 hours and represent safe correction trajectories requiring continued monitoring.
Option A: Option A is incorrect: a rise of 6 mEq/L in 24 hours is within the safe target range; this trajectory should be continued with monitoring.
Option C: Option C is incorrect: a rise of 7 mEq/L in 24 hours is within the safe target range; 12-hour monitoring checks are appropriate and the rate is acceptable.
Option D: Option D is incorrect: a rise of 8 mEq/L in 24 hours is at the upper boundary of the safe target range but does not exceed the absolute ceiling; careful monitoring is the correct response.
Option E: Option E is incorrect: a rise of 5 mEq/L in 24 hours is within the safe target range; twice-daily sodium checks are appropriate for ongoing vaptan therapy.
20. A patient with mild hemophilia A is given desmopressin once daily for three consecutive days before and after a dental procedure. On day 1, factor VIII (a clotting protein) rises from 20% of normal to 68% — excellent hemostatic coverage. On day 2, the same dose raises factor VIII only to 44%. On day 3, the dose raises factor VIII only to 26% — barely above baseline and insufficient for hemostatic coverage. Applying what you learned about Weibel-Palade bodies in Q9, what explains this pattern?
A) The patient has developed antibodies against desmopressin by day 3; the immune response neutralizes the drug before it can reach V2 receptors on endothelial cells, explaining the progressively smaller response with each dose.
B) The V2 receptors on endothelial cells become desensitized after repeated stimulation; by day 3, fewer surface receptors are available and the cyclic AMP signal generated per dose is insufficient to trigger exocytosis of Weibel-Palade bodies.
C) By day 3, the liver has induced the enzyme that metabolizes desmopressin, causing the drug to be cleared faster; lower plasma levels of desmopressin reach the endothelial cells and trigger a proportionally smaller response.
D) The factor VIII stored in Weibel-Palade bodies is converted to an inactive form by repeated desmopressin stimulation; by day 3, the released protein is still present in the blood but has lost its coagulation activity.
E) Each daily dose of desmopressin triggers the Weibel-Palade bodies to release their stored contents; once released, the factor VIII and vWF stores require approximately 24 to 48 hours to fully replenish; with daily dosing the storage pool is depleted faster than it can be restocked, so each successive dose releases progressively less — even though the V2 receptor and the signaling cascade are working perfectly on all three days.
ANSWER: E
Rationale:
This bridge question applies the Weibel-Palade body mechanism from Q9 to predict the trajectory of repeated desmopressin dosing. In Q9 we established that Weibel-Palade bodies are the storage organelles in endothelial cells and that desmopressin triggers their exocytic release of vWF and factor VIII. A key feature of this mechanism is that the release is from a preformed, finite storage pool — desmopressin cannot produce more factor VIII than the Weibel-Palade bodies currently contain. After a dose depletes the pool, new factor VIII and vWF must be synthesized and packaged into new Weibel-Palade bodies — a process that takes approximately 24 to 48 hours. With once-daily dosing, the pool is never fully restored between doses. The Day 1 response is full because the pool is complete. The Day 2 response is smaller because only partial replenishment has occurred in the 24 hours since Day 1. By Day 3, the pool is largely exhausted and the same dose of desmopressin — activating V2 receptors perfectly normally and generating normal cAMP levels — finds very little remaining in the granules to release. This gradual loss of hemostatic response with repeated dosing is called tachyphylaxis. It is not a receptor problem, not an immune problem, not a drug clearance problem — it is simply storage biology. This is why desmopressin is appropriate for short-duration hemostatic coverage of 2 to 3 days but is not suitable for procedures requiring sustained support over 4 or more days.
Option A: Option A is incorrect: desmopressin is a small peptide; meaningful antibody formation against it within 3 days of treatment is not an established clinical phenomenon; tachyphylaxis to desmopressin is a pharmacodynamic storage event, not immunological.
Option B: Option B is incorrect: V2 receptor desensitization causing reduced cAMP generation is not the established mechanism of desmopressin tachyphylaxis; the V2 signaling cascade remains functional; the storage pool depletion is the explanation.
Option C: Option C is incorrect: desmopressin does not induce its own metabolizing enzyme; hepatic enzyme induction requires days to weeks; the declining response over 3 days is not a pharmacokinetic phenomenon.
Option D: Option D is incorrect: factor VIII is not converted to an inactive form by repeated desmopressin stimulation; the released factor VIII is fully functional on all three days; the decline in response is due to less being released, not to functional inactivation of what is released.
21. Using the signaling pathway described in Q2 (V2 receptor → cyclic AMP → protein kinase A → AQP2 insertion into collecting duct membrane), identify precisely what tolvaptan prevents at the molecular level, and explain why this causes dilute urine to be excreted rather than reabsorbed.
A) Tolvaptan enters collecting duct cells and directly degrades AQP2 protein inside the vesicles; without any AQP2 protein to insert, the luminal membrane remains impermeable to water even if the V2 receptor is activated by AVP.
B) Tolvaptan blocks the cyclic AMP phosphodiesterase enzyme inside collecting duct cells, causing cyclic AMP to accumulate to toxic levels that prevent protein kinase A from functioning; the upstream V2 receptor is unaffected but the downstream signaling is paralyzed.
C) Tolvaptan occupies the V2 receptor on the collecting duct cell surface, blocking AVP from binding; because the receptor cannot be activated, the Gs signaling chain does not fire, cyclic AMP is not generated, protein kinase A is not activated, and AQP2 vesicles remain stored inside the cell rather than being inserted into the luminal membrane — the urine side of the collecting duct has no water channels, so the dilute filtrate cannot cross into the cell and is excreted as dilute urine.
D) Tolvaptan prevents the synthesis of new AQP2 protein by blocking the V2 receptor's ability to activate the transcription factor that controls the AQP2 gene; over several days, existing AQP2 protein degrades and is not replaced, gradually reducing water reabsorption capacity.
E) Tolvaptan binds directly to the AQP2 water channel protein and blocks its central pore; AQP2 channels are still inserted into the luminal membrane normally in response to AVP, but tolvaptan physically occludes the pore so water cannot pass through.
ANSWER: C
Rationale:
This question requires applying the full signaling pathway from Q2 to identify exactly where tolvaptan intervenes. The pathway has four steps: (1) AVP binds V2 receptor → (2) Gs protein activates adenylyl cyclase → (3) cyclic AMP rises → (4) protein kinase A phosphorylates AQP2 vesicles → AQP2 moves to luminal membrane → water enters cell. Tolvaptan is a competitive antagonist at the V2 receptor — it occupies the same binding site that AVP would use, blocking AVP from binding. Because the receptor is blocked at step 1, none of the downstream steps can occur: no Gs activation, no cyclic AMP generation, no protein kinase A activation, and no AQP2 insertion into the luminal membrane. The collecting duct luminal membrane remains water-impermeable. The tubular fluid — which has already been largely cleared of electrolytes by upstream nephron segments and is relatively dilute — cannot cross the water-impermeable membrane, so it flows through and is excreted as dilute urine. This is aquaresis: the excretion of electrolyte-free water. Understanding which step is blocked matters because it explains why tolvaptan and desmopressin have opposite effects in the kidney: desmopressin activates V2 receptors and drives AQP2 insertion; tolvaptan blocks V2 receptors and prevents it.
Option A: Option A is incorrect: tolvaptan does not enter collecting duct cells and degrade AQP2 protein; it acts extracellularly at the V2 receptor on the cell surface without entering the cell or directly touching AQP2 protein.
Option B: Option B is incorrect: tolvaptan does not block phosphodiesterase; phosphodiesterase degrades cyclic AMP (which would reduce the signal); tolvaptan acts upstream at the receptor, preventing cyclic AMP from being generated at all; blocking phosphodiesterase would actually increase cyclic AMP, producing the opposite of tolvaptan's effect.
Option D: Option D is incorrect: tolvaptan's effect on AQP2 expression is not primarily transcriptional; blocking AQP2 gene transcription is a long-term adaptation that occurs with chronic V2 blockade, but tolvaptan's immediate pharmacological effect is receptor blockade preventing AQP2 vesicle trafficking — not transcriptional repression of protein synthesis.
Option E: Option E is incorrect: tolvaptan does not bind to AQP2 channels or physically block their pore; it acts at the V2 receptor, upstream of AQP2; the water channel itself is not the drug's target.
22. Four patients all have SIADH with sodium of 124 mEq/L and are being evaluated for tolvaptan. Using the thirst-buffer concept — that a patient on tolvaptan must be able to drink freely in response to thirst to buffer the aquaresis-driven sodium rise — which patient represents the highest risk for a dangerous sodium overcorrection on tolvaptan?
A) A 79-year-old woman with advanced dementia who does not reliably perceive or express thirst, cannot request water independently, and requires staff assistance for all oral intake; her care team documents that she often goes many hours without drinking even when water is placed nearby.
B) A 52-year-old man who drinks 2 liters of coffee per day and reports that he is always thirsty; the team is concerned he may drink too much fluid and prevent the sodium from rising at all.
C) A 61-year-old woman with chronic kidney disease (eGFR 35 mL/min) who takes a daily multivitamin; the team is concerned that the reduced kidney function will prevent tolvaptan from being cleared and cause accumulation.
D) A 44-year-old man who is reluctant to check sodium levels frequently because he dislikes needlesticks; he is otherwise alert, oriented, and capable of drinking freely.
E) A 38-year-old woman who works as a nurse and understands her condition well; she asks many questions about tolvaptan and is eager to participate in her own care.
ANSWER: A
Rationale:
This final bridge question applies the thirst-buffer concept from Q11 — combined with the absolute contraindication introduced in the T1 and T3 sets — to patient selection. The safety of tolvaptan depends entirely on the patient being able to drink enough water to buffer the aquaresis-driven sodium rise. When thirst is triggered by rising plasma osmolality, the patient must be able to (1) perceive the thirst signal, and (2) physically obtain and drink water in response. If either of these is absent, the sodium can rise to dangerous levels unchecked. The patient in option A is at the highest risk: advanced dementia impairs both thirst perception and the ability to communicate thirst and act on it independently; the documented behavior of going hours without drinking even when water is available confirms that the thirst-drive feedback loop is not functioning reliably. Administering tolvaptan to this patient would produce aquaresis with no effective buffer — a high risk of severe hypernatremia and potential osmotic injury. Before initiating any vaptan, the prescribing team must confirm that the patient has intact thirst sensation and unrestricted access to oral fluids; this is an absolute prerequisite.
Option B: Option B is incorrect: a patient who drinks freely in response to thirst is actually the ideal tolvaptan candidate; excessive drinking might blunt the sodium-raising effect somewhat, but it does not cause the dangerous overcorrection that results from insufficient drinking.
Option C: Option C is incorrect: tolvaptan is eliminated by hepatic metabolism with fecal excretion, not by renal clearance; reduced eGFR does not cause clinically significant tolvaptan accumulation; a multivitamin is not a CYP3A4 inhibitor; this patient does not have the specific safety risk described.
Option D: Option D is incorrect: reluctance to have blood drawn is a compliance issue that requires patient education, but it is not the same as inability to drink in response to thirst — this patient is alert and capable of the physiological buffering needed; the sodium monitoring concern can be addressed through conversation.
Option E: Option E is incorrect: an alert, informed patient who actively participates in her care represents the lowest-risk profile for tolvaptan among these choices; her ability to understand, perceive thirst, and drink freely makes her an appropriate candidate.
BEFORE YOU MOVE ON
You have just worked through the foundational pharmacology of the vasopressin system — from the hormone itself and the two receptor subtypes that carry its signals, through the drugs that mimic it (desmopressin), block it (vaptans), and the clinical situations that make each approach necessary. You built a vocabulary of terms — aquaresis, SIADH, ODS, Weibel-Palade bodies — and then used that vocabulary to reason through real clinical decisions: why a low urine sodium redirects treatment from a vaptan to saline, why combining fluid restriction with tolvaptan removes a critical safety buffer, why desmopressin given repeatedly across three days produces a smaller response each time. These are not isolated facts. They are a connected system, and the connections are what will carry you into the tiers above.
This is the fourth module in the Vasoactive Peptide Pharmacology series, and by now the pattern of the series should be familiar: each module targets a distinct arm of the peptide pharmacology landscape — natriuretic peptides, kinins, endothelin, and now vasopressin — and together they build a picture of how the body regulates fluid, blood pressure, and vascular tone through chemical messengers that clinicians can amplify, block, or replace. Vasopressin sits at the center of clinical sodium management, and the drugs in this module appear repeatedly in ICU management, nephrology consultations, hematology referrals, and endocrinology practice. You will encounter them.
The Foundational Recall questions ahead will ask you to discriminate precisely — the exact G protein for each receptor subtype, the exact structural modification responsible for each desmopressin property, the exact duration limit for each approved vaptan. The questions you just answered gave you the conceptual framework that makes those precise distinctions meaningful rather than arbitrary. Go in knowing that the precision you are about to encounter is built on the foundations you just laid.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.